- Obesity drug trials will dominate
- Oncology is still an important area
It is going to be an interesting year for many pharmaceutical and biotechnology companies as key trial results in the first half of 2025 are expected to point to the trends that will dominate the narrative. To begin with, a boost is needed as last year proved to be a relatively disappointing one for many biotech companies, with lower levels of acquisitions and failed IPOs contributing to a sustained fall in valuations both here and in the US. Therefore, the industry needs a few wins from forthcoming trial results and takeovers to regain momentum.
One platform for doing this was the JP Morgan healthcare conference in San Francisco this week, and some companies decided to get ahead of the news cycle for one of the pharmaceutical industry’s most important annual events.